The impact on carbamazepine usage and cutaneous adverse reactions before and after the reimbursement of HLA-B*1502 genotyping in Taiwan, 2000-2017: A nationwide longitudinal study.
Bao-Luen ChangJia-Rou LiuShu-Hao ChangLai-Chu SeePublished in: Epilepsia (2023)
Recognizing HLA-B*1502 allele and avoiding CBZ therapy in HLA-B*1502-positive patients is critical for preventing CBZ-induced severe adverse events.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- high glucose
- genome wide
- emergency department
- stem cells
- gene expression
- cross sectional
- diabetic rats
- early onset
- patient reported outcomes
- dna methylation
- bone marrow
- cell therapy
- single cell
- adverse drug
- smoking cessation